-
Even if the weight is normal, the body fat index is also related to the risk of cancer
Time of Update: 2021-04-27
The association of body fat composition with risk of breast, endometrial, ovarian and colorectal cancers among normal weight participants in the UK Biobank.
-
Professor Xu Wei: Diagnosis and Differential Diagnosis of CLL | The 4th China Conference on Chronic Lymphocytic Leukemia
Time of Update: 2021-04-27
) The International Chronic Lymphocytic Leukemia Working Group (iwCLL) "Chronic Lymphocytic Leukemia Diagnosis, Treatment Indications, Efficacy Evaluation and Supportive Treatment Guidelines (2018 version)” pointed out: Regardless of the number of peripheral blood B lymphocytes or lymph node involvement, cytopenias caused by typical bone marrow infiltration are diagnosed as CLL.
-
Aiming to solve the problem of side effects of IL-2 immunotherapy, Xinrui completes US$55 million in Series A financing
Time of Update: 2021-04-27
▲The "cis-targeting" strategy requires the therapeutic protein to bind to two different molecules on the cell at the same time to be able to work (picture source: Asher Biotherapeutics company official website) In preclinical experiments, AB248 significantly activates CD8-positive T cells At the same time, it hardly activates natural killer cells and Treg cells.
-
JAMA Sub-Journal: These advanced breast cancers are expected to be cured! Chinese scholars propose to modify the stage of the disease
Time of Update: 2021-04-27
Recently, JAMA Network Open, a sub-issue of the Journal of the American Medical Association, published a case analysis study that showed that stage IV breast cancer with distant lymph node metastasis can be regarded as a local disease and is expected to be cured through active treatment.
-
Harvard scientists discovered an anti-cancer target that can not only affect tumor cells and improve the immune microenvironment, but also improve the anti-cancer activity of immune cells 丨 scientific discovery
Time of Update: 2021-04-27
Specifically, not only has the anti-cancer activity of T cells increased, but also the ability of T cells whose Carm1 gene has been knocked out to enter tumors has also increased.
-
A new treatment plan for advanced renal cell carcinoma-lenvatinib combined with pembrolizumab
Time of Update: 2021-04-27
In a multinational phase 3 trial, patients with previously untreated advanced renal cell carcinoma were randomly divided into 3 groups and received lenvatinib + pembrolizumab (Len/Pem; lenvatinib daily, Pembrolizumab is administered intravenously every 3 weeks), lenvatinib + everolimus (Len/Eve; both drugs are administered daily) or sunitinib (treatment for 4 weeks, drug withdrawal for 2 weeks) treatment.
-
To accurately predict the prognosis of early lung cancer patients <3cm, GGO component analysis is essential
Time of Update: 2021-04-27
*Only for medical professionals to read for reference. According to the eighth edition of TNM staging, what effect does GGO component have on the prognosis of patients? Research background The eight
-
Shanghai Jiaotong University Duan Yourong/Lin Houwen/Liao Hongze The development of new protein inhibitors has important reference significance for the control of tumor blood-borne metastasis
Time of Update: 2021-04-27
This study generally demonstrates the feasibility of using DR6/APP interaction to regulate transendothelial migration of blood-borne tumor cells, and provides PEG-tAHP-DRI as a DR6/APP interaction for the development of anti-blood-borne metastasis therapies A novel and promising inhibitor.
-
New Drug Development: Anti-HER3 Targeted Therapy 30 Years of Creeping Road
Time of Update: 2021-04-27
The pan-HER family inhibitor Sym013 is a mixture of six humanized full-length monoclonal antibodies against three targets of EGFR, HER2, and HER3, and has been shown to reduce the growth of cancer cells in vivo and in vitro.
-
Interpretation of the global consensus on screening and eradicating Hp and preventing gastric cancer is here! Important recommendation see here
Time of Update: 2021-04-27
This point is consistent with the "Expert Consensus Opinions on Helicobacter Pylori Eradication and Gastric Cancer Prevention and Control in China" published in my country in 2019 [3].
Screening and eradication of Helicobacter pylori for gastric cancer prevention: the Taipei global consensus.
-
Antibody-drug conjugate enfortumab vedotin prolongs survival of patients with metastatic urothelial carcinoma
Time of Update: 2021-04-27
This article from the NEJM meta-Journal (NEJM Journal Watch) Enfortumab Vedotin Improves Survival in Patients with Heavily Treated Metastatic Urothelial Cancerenfortumab vedotin prolong survival comment author has been heavily pre-treated patients with metastatic urothelial carcinoma: Robert Dreicer, MD, MS, MACP, FASCO In this phase 3 trial, all primary endpoints showed that enfortumab vedotin is more effective than chemotherapy.
-
CAR-T bitter journey
Time of Update: 2021-04-27
At the same time, solid tumors lack chemokines (expressed at low levels in solid tumors) that can drive CAR-T cells to migrate to target cells.
The above obstacles make even CAR-T cells in After finding the target, it is also difficult to penetrate into the tumor tissue.
-
FDA News | Pembrolizumab combination program approved as first-line treatment for advanced esophageal cancer or GEJ cancer
Time of Update: 2021-04-27
0001), and the risk of death was reduced by 27%; the 12-month OS was 51%, compared with the chemotherapy group (39%) Increased by 12%; median PFS was 6.
-
ESMO releases clinical practice guidelines for small cell lung cancer; domestic marketing application for the third-generation ALK inhibitor loratinib has been accepted|Tumor News
Time of Update: 2021-04-23
03CCR: The use of dexrazoxane did not reduce the progression-free survival of patients with soft tissue sarcoma receiving first-line doxorubicin treatment.
-
After breast cancer surgery, why did she have hot flashes, sweating, body aches and restlessness?
Time of Update: 2021-04-23
Due to the decreased synthesis of endogenous estrogen, patients are not only prone to symptoms such as hot flashes and sweating, but also due to accelerated bone loss, it is easy to induce or aggravate osteoporosis and increase the risk of fracture [2].
-
Professor Shusen Wang: Update points and interpretation of advanced triple-negative breast cancer treatment guidelines
Time of Update: 2021-04-23
Rescue treatment strategy for advanced triple-negative breast cancer: Update of rescue treatment: For patients who have failed anthracycline therapy, level II recommends the addition of albumin paclitaxel + PD-L1/PD-1 inhibitor (category 2A); level III recommends new The level of evidence for olaparib (Class 2A), chemotherapy + PD-1/PD-L1 inhibitor (Class 2B), and paclitaxel liposomes was updated to Class 2A.
-
Solve the "Achilles' Heel" of CAR-T!
Time of Update: 2021-04-23
com" target="_blank">The results showed that under the recommended phase 2 dose of lenzilumab, the objective response rate (ORR) reached 100%, and no patients had severe cytokine release syndrome (CRS) or severe neurotoxicity (NT).
-
Genome Medicine | Zhao Quan's research group at Nanjing University discovers new histone modification recognition effector molecules and cancer treatment applications
Time of Update: 2021-04-23
On April 14, 2021, Zhao Quan's team from the School of Life Sciences, Nanjing University published a research paper PRMT1-mediatedH4R3me2a recruits SMARCA4 to promote colorectal cancer progression by enhancing EGFR signaling in the internationally renowned journal Genome Medicine (IF=10.
-
Schlafen 5: A new target for the treatment of pancreatic cancer
Time of Update: 2021-04-23
Studies have confirmed that in the in vivo PDAC model, the targeted deletion of SLFN5 does cause the decline of PDAC cell proliferation and inhibit the growth of PDAC tumors.
-
Molecular Cancer | Continuous progress!
Time of Update: 2021-04-23
In summary, this study reveals a potential new mechanism for the deregulation of miR-144/miR-451a clusters and the crosstalk between malignant cells and tumor-associated macrophages (TAM) in HCC, providing new insights into the pathogenesis and diagnostic strategies of HCC .
